Skip to Content

Connectyx Technologies Holdings Group Inc CTYX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Connectyx Technologies Holdings Group Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The company is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. The company's product development engine rests on the S.O.A.R. i.e. Science, Opportunity, Acceleration, Rare Disease. The company expects to rename itself as Curative Biotech.

Contact
1825 NW Corporate Boulevard, Suite 110
Boca Raton, FL, 33431
T +1 561 418-7725
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Slow Growth
Employees